Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple interaction- and mechanism-related claims are not supported by the provided label excerpts (e.g., furanocoumarins specifics, CYP3A4 binding mechanism, hepatic levels, bleeding/anticoagulant relevance, antioxidants/anti-inflammatory benefits). One claim is directly contradicted by the label framing (absolute 'avoid altogether' vs quantity-threshold guidance).
Category Scores
Accurate Statements
Lipitor works by inhibiting the production of cholesterol in the liver.
Supported by 12.1 Mechanism of Action (HMG-CoA reductase inhibition; cholesterol synthesis in the liver).
Lipitor reduces low-density lipoprotein (LDL) or "bad" cholesterol in the bloodstream.
Supported by 12.1 Mechanism of Action (reduces LDL-C).
Reduced CYP3A4 activity from grapefruit can lead to increased levels of Lipitor in the bloodstream.
Supported by 7.2 Grapefruit Juice (inhibits CYP 3A4 and can increase plasma concentrations of atorvastatin).
Unsupported Statements
Lipitor is a statin medication used to lower cholesterol levels in the blood.
Provided excerpt supports lipid-altering effects (e.g., LDL-C reduction) but does not explicitly support the exact 'used to lower cholesterol levels in the blood' phrasing as an indication statement.
Lipitor helps to prevent the buildup of plaque in the arteries that can lead to heart disease and stroke.
Provided excerpts do not explicitly state plaque-buildup prevention or prevention of heart disease/stroke.
Grapefruit contains furanocoumarins.
7.2 states components that inhibit CYP 3A4; the provided excerpt does not state 'furanocoumarins' specifically.
Furanocoumarins inhibit the activity of the enzyme CYP3A4.
Label excerpt does not explicitly link 'furanocoumarins' to inhibition of CYP 3A4.
CYP3A4 is responsible for metabolizing many medications, including Lipitor.
Provided excerpt does not state CYP 3A4 is responsible for metabolizing atorvastatin.
When grapefruit is consumed, furanocoumarins can bind to CYP3A4.
Label excerpt states inhibition of CYP 3A4, but does not describe 'binding' or 'furanocoumarins'.
Binding to CYP3A4 reduces its activity.
Label excerpt supports CYP 3A4 inhibition by grapefruit juice components but does not support the 'binding' mechanism phrasing.
Elevated levels of Lipitor in the bloodstream can increase the risk of muscle damage (rhabdomyolysis).
Label excerpt supports rhabdomyolysis as a serious adverse reaction and supports increased atorvastatin exposure with grapefruit, but does not explicitly connect grapefruit-driven increased exposure to rhabdomyolysis risk.
Grapefruit's impact on CYP3A4 can lead to increased levels of Lipitor in the liver.
Provided excerpt only states increased plasma concentrations, not liver concentrations.
Increased levels of Lipitor in the liver can potentially cause liver damage.
Provided excerpt discusses liver enzyme abnormalities and contraindication criteria, but does not link grapefruit interaction to increased hepatic atorvastatin causing liver damage.
Grapefruit's interaction with Lipitor may increase the risk of bleeding.
Provided grapefruit interaction and other excerpts do not mention bleeding risk.
The increased risk of bleeding from grapefruit-Lipitor interaction may be particularly relevant in patients taking anticoagulant medications.
No bleeding/anticoagulant relevance is stated in the provided label excerpts.
Grapefruit contains antioxidants, including vitamin C and beta-carotene, which can help protect against oxidative stress and inflammation.
Provided label excerpt does not discuss antioxidants, vitamin C, or beta-carotene.
Grapefruit's flavonoids have anti-inflammatory properties.
Provided label excerpt does not discuss flavonoids or anti-inflammatory properties.
Grapefruit's anti-inflammatory properties may help reduce the risk of chronic diseases such as heart disease and cancer.
Provided label excerpt does not support these disease-risk claims.
The risk of adverse effects from grapefruit-Lipitor interactions is relatively low.
No relative magnitude ('relatively low') is stated in the provided label excerpts.
The risk of adverse effects from grapefruit-Lipitor interactions is not zero.
No 'not zero' phrasing or equivalent risk magnitude is stated in the provided label excerpts.
Patients should be aware of the potential risks and benefits before consuming grapefruit while taking Lipitor.
Label counseling provided supports reporting risks and specifies increased risk with larger grapefruit juice quantities, but does not include 'risks and benefits' balancing language.
Grapefruit juice is a more concentrated source of furanocoumarins than fresh grapefruit.
Provided excerpt does not compare fresh grapefruit vs juice or mention furanocoumarin concentration differences.
Patients taking Lipitor should consult their doctor or pharmacist before consuming grapefruit.
Label advises discussion with healthcare professional and gives threshold-based counseling, but does not explicitly require 'consult their doctor or pharmacist before consuming grapefruit' as phrased.
Grapefruit juice is more likely to cause interactions than fresh grapefruit.
Provided excerpt does not explicitly compare interaction likelihood between juice and fresh grapefruit.
Grapefruit contains antioxidants and anti-inflammatory compounds that may have beneficial effects.
Provided label excerpt does not describe beneficial antioxidant/anti-inflammatory effects.
Contradictions
Low
AI Statement
Grapefruit juice is best to avoid altogether.
Label Reference
7.2 Grapefruit Juice and 17.1 Muscle Pain describe increased risk especially with excessive/larger consumption (e.g., >1.2 liters/day or >1 liter), not an absolute 'avoid altogether' instruction.
Important Omissions
No label-referenced quantity threshold for increased grapefruit juice exposure (e.g., >1.2 liters/day; increased risk with larger quantities >1 liter) is provided in the AI-extracted claims where relevant to safe interaction context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and overly specific mechanistic claims (e.g., bleeding/anticoagulants; hepatic vs plasma; furanocoumarin-binding) plus an absolute 'avoid altogether' message that conflicts with label quantity-threshold guidance could mislead risk assessment and counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous interaction/mechanism/benefit claims are not supported by the provided label excerpts, and one claim is directly contradicted (absolute avoidance).
Suggested Improvement
Restrict grapefruit/interaction statements to what the provided label supports: grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin (especially with excessive consumption >1.2 L/day), and counseling emphasizes increased myopathy risk with larger quantities (>1 liter) and prompt reporting of unexplained muscle symptoms; avoid unsupported mechanistic details (furanocoumarin binding), unsupported risks (bleeding/anticoagulants), and unsupported antioxidant/anti-inflammatory benefit claims.